biote Corp - Class A
Research biote Corp - Class A (BTMD) on Bullrun: valuation model: 104.2% undervalued, market cap USD 50.65M, P/E 3.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBTMD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Care Facilities
- CurrencyUSD
- Valuation signal104.2% undervalued
- Market capUSD 50.65M
- P/E3.7
- Financial periodFY2025
- RevenueUSD 192.22M
- Revenue growth-2.5%
- Net incomeUSD 27.05M
- Free cash flowUSD 30.18M
Valuation Snapshot
Bullrun's latest valuation model marks biote Corp - Class A as 104.2% undervalued; latest market cap is USD 50.65M; P/E is 3.7.
About biote Corp - Class A
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.
Frequently asked questions
Is biote Corp - Class A overvalued or undervalued?
Bullrun's valuation model currently marks biote Corp - Class A as 104.2% undervalued.
What is biote Corp - Class A's market cap?
biote Corp - Class A's market capitalization is USD 50.65M.
What is biote Corp - Class A's P/E ratio?
biote Corp - Class A's price-to-earnings (P/E) ratio is 3.7.
What does biote Corp - Class A do?
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.